Article
Oncology
Mohamed E. Salama, Gregory E. Otteson, Jon J. Camp, Jansen N. Seheult, Dragan Jevremovic, David R. Holmes, Horatiu Olteanu, Min Shi
Summary: Flow cytometric immunophenotyping is critical in detecting minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). In this study, a deep neural network (DNN) approach was evaluated for its performance in detecting CLL MRD, and it was found to have high accuracy and improve workflow efficiency.
Review
Oncology
Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk
Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.
Article
Oncology
Janine Stutterheim, Inge M. van der Sluis, Paola de Lorenzo, Julia Alten, Philip Ancliffe, Andishe Attarbaschi, Benoit Brethon, Andrea Biondi, Myriam Campbell, Giovanni Cazzaniga, Gabriele Escherich, Alina Ferster, Rishi S. Kotecha, Birgitte Lausen, Chi Kong Li, Luca Lo Nigro, Franco Locatelli, Rolf Marschalek, Claus Meyer, Martin Schrappe, Jan Stary, Ajay Vora, Jan Zuna, Vincent H. J. van der Velden, Tomasz Szczepanski, Maria Grazia Valsecchi, Rob Pieters
Summary: MRD levels are predictive of outcomes in infant acute lymphoblastic leukemia, helping to guide treatment interventions.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Gloria Paz Contreras Yametti, Talia H. Ostrow, Sylwia Jasinski, Elizabeth A. Raetz, William L. Carroll, Nikki A. Evensen
Summary: Acute lymphoblastic leukemia minimal residual disease (MRD) is residual leukemia cells present after achieving complete remission, with significant impact on prognosis. Rapid reduction of MRD indicates leukemia sensitivity to therapy, aiding in risk stratification and treatment adjustment.
Review
Medicine, General & Internal
Davide Lazzarotto, Anna Candoni
Summary: Monitoring Minimal Residual Disease (MRD) is crucial in acute myeloid leukemia (AML) for guiding treatment, determining the need for stem cell transplantation, and detecting relapse early. However, more than 50% of AML patients lack specific molecular markers for MRD monitoring. This review focuses on the use of WT1 overexpression as an MRD marker in AML patients undergoing intensive chemotherapy, including stem cell transplantation. The standardized method of European LeukemiaNet is recommended for achieving optimal sensitivity and specificity.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty
Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.
Article
Oncology
Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak
Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.
Article
Oncology
Huirong Mai, Qin Li, Guobing Wang, Ying Wang, Shilin Liu, Xue Tang, Fen Chen, Guichi Zhou, Yi Liu, Tonghui Li, Lulu Wang, Chunyan Wang, Feiqiu Wen, Sixi Liu
Summary: This study explored the feasibility of using Next-generation sequencing (NGS) technology to detect minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL). The results showed that NGS is more sensitive than multiparametric flow cytometry (MFC) and real-time quantitative PCR (RQ-PCR) in detecting MRD. Furthermore, the number of clonal rearrangement sequences detected by NGS before treatment is an independent factor in predicting whether MRD can become negative after chemotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Immunology
Jia-Nan Li, Yu Li, Ji-Xun Lin, Li-Na Wang, Xiao-Li Zhang, Juan Ouyang, Du-Bo Chen, Shao-Qian Chen, Jun-Xun Li, Xue-Qun Luo, Yan-Lai Tang, Li-Bin Huang
Summary: This study observes the effectiveness of chemotherapy combined with CD19 and CD20 monoclonal antibodies in children with refractory B-ALL. The results show that this treatment can improve remission rate and serve as a bridge to transplantation.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Chih-Hsiang Yu, Shiann-Tarng Jou, Ying-Hui Su, Elane Coustan-Smith, Gang Wu, Chao-Neng Cheng, Meng-Yao Lu, Kai-Hsin Lin, Kang-Hsi Wu, Shu-Huey Chen, Fang-Liang Huang, Hsiu-Hao Chang, Jinn-Li Wang, Hsiu-Ju Yen, Meng-Ju Li, Shu-Wei Chou, Wan-Ling Ho, Yen-Lin Liu, Chia-Ching Chang, Ze-Shiang Lin, Chien-Yu Lin, Hsuan-Yu Chen, Yu-Ling Ni, Dong-Tsamn Lin, Shu-Wha Lin, Jun J. Yang, Yen-Hsuan Ni, Ching-Hon Pui, Sung-Liang Yu, Yung-Li Yang
Summary: This study analyzed data from two consecutive protocols to determine the clinical impact of minimal/measurable residual disease (MRD) and tumor genetic subtypes in newly diagnosed pediatric acute lymphoblastic leukemia (ALL) patients. The results showed that MRD-directed therapy improved outcomes for pediatric ALL, especially for standard-risk patients. This study provides important data to inform the design of future clinical trials in Taiwan.
Article
Oncology
Alexandre Bazinet, Ryan N. Rys, Amadou Barry, Celia M. T. Greenwood, Yoon Kow Young, Alma Mendoza, Ida LaPorta, Claudia M. Wever, Francois E. Mercier, Nathalie A. Johnson
Summary: By adding CD23 and CD200 to the EuroFlow(TM) lymphoid screening tube, a 10-color modified LST (mLST) capable of diagnosing typical CLL in a single tube was created. After 1 year of clinical use, the mLST diagnosed CLL without further immunophenotyping in 56% of samples with an abnormal clone and showed good agreement in MRD results with the ERIC panel.
LEUKEMIA & LYMPHOMA
(2021)
Article
Hematology
Anjali S. Advani, Anna Moseley, Kristen M. O'Dwyer, Brent L. Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Summary: This study evaluated the feasibility and outcomes of the combination of blinatumomab, dasatinib, and steroids for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in older patients. The results showed that this combination therapy was safe and effective, with a 3-year overall survival rate of 87% and a disease-free survival rate of 77%.
Article
Hematology
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O'Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Summary: The ZUMA-3 study evaluated the efficacy and safety of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. The treatment showed a high response rate and tolerable safety profile, with revised adverse event management strategies helping to optimize the risk-benefit ratio.
Article
Oncology
Ekaterina Mikhailova, Olga Illarionova, Alexander Komkov, Elena Zerkalenkova, Ilgar Mamedov, Larisa Shelikhova, Yulia Olshanskaya, Natalia Miakova, Galina Novichkova, Alexander Karachunskiy, Michael Maschan, Alexander Popov
Summary: This study aimed to develop an antibody panel and data analysis algorithm for reliable minimal residual disease (MRD) detection in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients treated with CD19-directed therapy. The approach was adapted for possible CD19 loss and showed high qualitative concordance rates when compared to molecular techniques.
Review
Medical Laboratory Technology
Jingjing Zhang, Jean Oak
Summary: Measurable/minimal residual disease (MRD) tracking is a powerful tool for assessing treatment response and predicting outcomes in acute leukemia. However, clinical and technological challenges need to be addressed to improve its utility in routine patient care.
SEMINARS IN DIAGNOSTIC PATHOLOGY
(2023)